Senior Medical Affairs leader with experience in country and above-country positions, including successful medical launches globally and in the US.Clinical Hemato-oncologist with 16 years of clinical practice before joining Pharma. Strong clinical and scientific (research and publication) history, as well as background in clinical research administration (including founding of an academic CRO).Experience in hematological and solid malignancies, Cell & Gene Therapy (CAR-T), as well as non-oncologic hematology (Aplastic Anemia, Thrombocytopenia and Sickle Cell Disease)Very well published and with broad understanding of oncology biologics and immune therapeutic development in a rapid changing clinical practice environment. Significant experience leading cross-functional teams including, field medical, clinical development, access and regulatory functions.Strong interpersonal and communication skills. Leader of interdisciplinary teams for the development and implementation of national, regional and global education as well as real world evidence projects.Past Appointment: (July 2018-July 2020): Novartis US. VP Hematology and CAR-T. Reporting to the Chief Medical Officer and led three medical groups: malignant hematology, benign hematology, and Cell & Gene (CAR-T).(Sept 2017-July 2018): Astrazeneca, Medical Franchise Head (Executive Medical Director), Lung Cancer, US Oncology Medical Affairs, Gaithersburg, MD.Previous Appointment: (June 2014-Aug 2017): Oncology Sr. Medical Director, International Region, Astrazeneca (Latin America, Asia-Pacific, China, Australia-NZ, Middle East and Africa & Russia, supporting Medical Affairs Japan). Based in the UK.Previous Appointment (Dec 2012-June 2014): Medical Director, Oncology. Bristol-Myers-Squibb México.Previous Appointment (Jan 2010 Dec 2012): Senior Medical Advisor Boehringer-Ingelheim Oncology, for Mexico, Central America & Caribbean